96 results about "Bovine viral diarrhea virus BVDV" patented technology

Imino sugars, such as deoxynojirimycin (DNJ), are glucose analogues that selectively inhibit cellular α-glucosidase I and II (enzymes that process N-linked glycans in glycoprotein) and exhibit broad spectrum antiviral activities against many enveloped viruses. Previously we have reported a novel DNJ derivative, OSL-95II, with antiviral activity and reduced cytotoxicity. In order to develop imino sugars with more potent antiviral activity as well as improved toxicity profile, OSL-95II was modified by diversifying the nitrogen linked alkylated side chain. The antiviral activities were initially tested in bovine viral diarrhea virus (BVDV) infected MDBK cells, yielding several imino sugar derivatives with novel structure and superior antiviral activity and toxicity profile. Furthermore, these new compounds were shown to be active against Dengue virus (DV) and West Nile virus (WNV) infection in BHK cells where potent anti-DV activity having submicromolar EC50 values and SI of greater than 900. These compounds represent a new generation of iminio sugars and their analogues, having application in the clinical treatment of infection of DV and other members of flaviviridae.

The invention discloses a primer for detecting bovine viral diarrhea virus, a kit prepared by using the primer and used for detecting BVDV, and a CRISPR-Cas13 a-based bovine viral diarrhea virus detection method. The primer is 5'-GGGGAUUUAGACUACCCCAAAAACGAAGGGGACUAAAACGCCAUCCAACGAACUCACCACUGUUGCU-3'; the kit at least comprises the primer; a sample to be detected is added into the kit for detection. According to the CRISPR-Cas13 a-based bovine viral diarrhea virus detection method, a CRISPR-Cas13a system is successfully applied to nucleic acid detection of the BVDV for the first time, and whether the BVDV is contained or not can be identified only by adding a micro-scale sample. The CRISPR-Cas13 a-based bovine viral diarrhea virus detection method has high specificity and sensitivity. The method provides a wide prospect for early diagnosis of the BVDV.

The present invention relates to a series of novel imidazo[1,2-α]pyrrolo[3,2-c]pyridines (or also named 6H-1,3a,6-Tri-aza-αy-indacenes) and derivatives thereof, according to formula: (I); The present invention also relates to processes for the preparation of imidazo[1,2-α]pyrrolo[3,2-c]pyridines, their use as. a, medicine, their use to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with viruses belonging to the family of the Flaviviridae and more preferably infections with Bovine Viral Diarrhea virus (BVDV).

Methods for reducing the pathogen content of a biologically derived composition by illuminating the composition with at least one high-intensity, short duration pulse of incoherent polychromatic light in a broad spectrum. In the resultant treated compositions, biomolecules of interest remain biologically active. The content of pathogens, such as viruses, bacteria, pyrogens, fungi and / or prions, present in a biologically derived composition, such as blood serum, blood plasma or other blood product, including, insulin, transferrin, heparin, collagen, Factor VIII and / or Factor IX, or a composition containing monoclonal antibodies, proteins from genetically engineered cell lines or the like, is reduced by illumination with broad-spectrum pulsed light. The content of HIV-1, SV40, canine parvovirus or bovine viral diarrhea virus in a biologically derived composition is dramatically reduced with a single pulse of broad-spectrum light.

The present invention relates to improved diagnostic methods and kits for differentiating between (a) animals administered a chimeric pestivirus, and (b) animals infected with a wild-type bovine viral diarrhea virus (BVDV) or immunized with a conventional BVDV vaccine.